News this morning....
"Cellegy Reports That Nitric Oxide Donors and cGMP Mimetics Inhibit Tumor Cell Metastasis
Paper Presented at American Association for Cancer Research Annual Meeting
SOUTH SAN FRANCISCO, Calif., April 11 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. (Nasdaq: CLGY - news) announced positive study results on the involvement of nitric oxide (NO) and cGMP (cyclic guanosine monophosphate) mimetics in attenuating the metastasis of cancer cells. The study results were presented April 7th at the American Association for Cancer Research Annual Meeting in San Francisco. The paper's senior author is Charles Graham, Ph.D., a consultant to Cellegy and a researcher at Queen's University in Ontario, Canada. It was presented at the meeting by Lynne Postovit, a Ph.D. student in Dr. Graham's laboratory.
Previously, Dr. Graham's group reported that cancer cells (human breast cancer cells, MDA-MB-231 and mouse melanoma cells, B16F10) made resistant to chemotherapeutic agents, 5-fluorouracil and doxorubicin by hypoxia can be re-sensitized if the cells are exposed to nitroglycerin, a nitric oxide donor (see Cellegy press release dated December 18, 2001 at www.cellegy.com). In the more recent studies, Dr. Graham's team expanded these findings by demonstrating that both nitric oxide donors and the cGMP signaling pathway are involved in the regulation of an invasion associated cell surface molecule (urokinase receptor) as well as metastasis. |
